Listen to our latest Investing Matters Podcast episode 'Uncovering opportunities with investment trusts' with The AIC's Richard Stone here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,599.00
Bid: 1,594.50
Ask: 1,595.50
Change: -19.00 (-1.17%)
Spread: 1.00 (0.063%)
Open: 1,608.00
High: 1,615.00
Low: 1,575.00
Prev. Close: 1,618.00
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 3-Biden sets out plan to share 25 mln COVID-19 vaccine doses with the world

Thu, 03rd Jun 2021 16:56

(Adds reaction, background)

By Jeff Mason and Carl O'Donnell

WASHINGTON, June 3 (Reuters) - The White House laid out a
plan on Thursday for the United States to share 25 million
surplus COVID-19 vaccine doses with the world and said it would
lift some restrictions to allow other countries to more easily
buy U.S.-made supplies for vaccine production.

President Joe Biden said the United States would share the
vaccines without expectation of political favors in return. He
has pledged to share some 80 million COVID-19 vaccines
internationally this month.

The United States will donate nearly 19 million doses
through the COVAX international vaccine-sharing program, Biden
said in a statement. Through COVAX, some 6 million doses would
go to Latin America and the Caribbean, about 7 million doses to
South and Southeast Asia and roughly 5 million to Africa.

The remaining doses, amounting to just over 6 million, would
go directly from the United States to countries including
Canada, Mexico, India and South Korea, he said.

"We are sharing these doses not to secure favors or extract
concessions," Biden said. "We are sharing these vaccines to save
lives and to lead the world in bringing an end to the pandemic,
with the power of our example and with our values."

Although the United States is working through the COVAX
facility co-run by the World Health Organization, the White
House retains final say in which countries receive U.S. doses
and how many, said national security adviser Jake Sullivan.

The White House will base donation decisions on "factors
included achieving global coverage, responding to crises ... and
helping as many countries as possible," Sullivan said, adding
the United States intends to prioritize its neighbors, including
Canada, Mexico and countries in Central and South America.

Reuters reported last month that the United States was
considering prioritizing its own hemisphere, with Latin America
a beneficiary.

The 25 million doses would be delivered quickly, with some
going out as soon as Thursday, the White House said.

Biden has come under pressure from the world community to
share the U.S. surplus of COVID-19 vaccines.

For months, the White House remained focused on getting
Americans vaccinated as the coronavirus killed more than half a
million people in the United States.

But the president has promised the United States would
become a supplier to other countries and pledged to send abroad
at least 20 million doses of the Pfizer Inc/BioNTech SE
, Moderna Inc and Johnson & Johnson
vaccines, on top of some 60 million AstraZeneca Plc
doses he had already planned to give to other countries.

The 25 million doses Biden announced on Thursday will not
include supply from AstraZeneca, the White House said.

International organizations including the United Nations and
the World Bank welcomed the announcement. "It’s a good start,
and I am hoping that more doses will be made available," World
Bank President David Malpass told Reuters.

LIFTING SOME RESTRICTIONS

The White House is also removing special powers it granted
through the Defense Production Act (DPA) to certain vaccine
makers that received U.S. funding but do not yet have U.S.
approvals, including AstraZeneca, Sanofi SA/GlaxoSmithKline Plc
, and Novavax Inc.

The DPA ratings give U.S. producers priority access to
supplies and equipment needed to manufacture the vaccines that
are in short supply around the world. Lifting them could free up
raw materials for major vaccine makers elsewhere, especially the
Serum Institute of India (SII).

Invoking the DPA helped build a huge local vaccine
production system, while some companies overseas have struggled
to get needed supplies to ramp up vaccine production.

SII, the world's largest vaccine maker and a top supplier of
COVID-19 shots to low- and middle-income countries, had
criticized the use of the DPA, and Reuters reported in May that
a shortage of U.S.-made raw materials would hit production of
Novavax's vaccine.

"That is a start, at least – the Biden administration acting
to stop harming the global response. Now, we need a DPA for the
world," said Peter Maybarduk, access to medicines director at
consumer watchdog Public Citizen, which has argued the United
States should use the DPA to scale up global vaccine production.

White House COVID-19 adviser Jeff Zients said the United
States would continue to donate additional doses throughout the
summer as more supply becomes available.

Concern has been growing about the huge disparity in
vaccination rates in developing countries versus advanced
economies.

The International Monetary Fund and World Bank on Thursday
urged the Group of Seven advanced economies to release any
excess COVID-19 vaccines to developing countries as soon as
possible, and called on manufacturers to ramp up production to
benefit poor countries.

Pfizer has begun independently exporting millions of its
U.S.-made shots largely to countries in Central and South
America, Reuters reported last month.

Many Latin American countries have a dire need for COVID-19
vaccines as they combat outbreaks. Brazil has been one of the
world’s hardest-hit countries by the pandemic, reporting more
than 15 million cases and 400,000 deaths.

Peru this week revised its COVID-19 death toll, making it
the country with the worst per-capita fatality rate.
(Reporting by Jeff Mason and Carl O'Donnell; additional
reporting by Allison Martell and Andrea Shalal; Editing by Bill
Berkrot and Peter Cooney)

More News
3 Jun 2024 17:20

European shares kick-off June on a high note in anticipation of ECB rate cut

GSK tumbles as Zantac lawsuits allowed to proceed

*

Read more
3 Jun 2024 17:19

Pharma, energy stocks drag London's FTSE 100; ECB rate cut hopes cap losses

FTSE 100 down 0.2%, FTSE 250 up 0.8%

*

Read more
3 Jun 2024 17:00

LONDON MARKET CLOSE: FTSE 100 down amid shaky start in New York

(Alliance News) - The FTSE 100 in London closed lower on Monday, marking a mixed start to June, with GSK firmly at the bottom of the index.

Read more
3 Jun 2024 14:01

GSK immunotherapy bowel cancer drug works for 100% of patients

(Alliance News) - An immunotherapy drug could spare bowel cancer patients the need for surgery and chemotherapy after results showed it was effective in 100% of cases.

Read more
3 Jun 2024 11:58

LONDON MARKET MIDDAY: FTSE 100 up, while Labour commits to defence

(Alliance News) - Stock prices in London were up at midday, after data from S&P Global signalled a return to growth for the UK manufacturing sector.

Read more
3 Jun 2024 09:08

TOP NEWS: GSK vows to appeal adverse Delaware court ruling on Zantac

(Alliance News) - GSK PLC on Monday said it will appeal a US court ruling that it should face jury trials relating to cases concerning the heartburn drug, Zantac.

Read more
3 Jun 2024 08:37

LONDON MARKET OPEN: Stocks up amid slew of manufacturing PMIs

(Alliance News) - Stock prices in London opened higher on Monday, ahead of local purchasing managers index data, and comparative prints from several other major global economies.

Read more
3 Jun 2024 08:00

LONDON BRIEFING: FTSE 100 seen up; GSK defends ranitidine cancer claim

(Alliance News) - Stocks in London are set to open higher on Monday, ahead of a data-heavy week, kicked off by a slew of manufacturing purchasing managers' index readings.

Read more
3 Jun 2024 07:30

GSK to appeal Delaware ruling on jury trials in Zantac cancer cases

(Sharecast News) - GSK shares were down almost 10% on Monday after a US court ruled that jury trials could hear expert witnesses in 70,000 cases brought by cancer sufferers claiming its Zantac heartburn drug caused their condition.

Read more
1 Jun 2024 21:35

Delaware judge lets more than 70,000 Zantac lawsuits go forward

June 1 (Reuters) - A Delaware judge has allowed more than 70,000 lawsuits over discontinued heartburn drug Zantac to go forward, ruling that expert witnesses can testify in court that the drug may cause cancer.

Read more
1 Jun 2024 21:07

Delaware judge lets more than 70,000 Zantac lawsuits go forward

June 1 (Reuters) - A Delaware judge has allowed more than 70,000 lawsuits over discontinued heartburn drug Zantac to go forward, ruling that expert witnesses can testify in court that the drug may cause cancer.

Read more
31 May 2024 17:45

US FDA approves Moderna's RSV vaccine with lower-than-expected efficacy in its label

May 31 (Reuters) - The U.S. Food and Drug Administration approved Moderna's respiratory syncytial virus (RSV) vaccine, the company announced on Friday, giving it a shot at much-needed new revenue from a second product.

Read more
31 May 2024 16:01

US FDA approves Moderna's RSV vaccine, its second marketed product

May 31 (Reuters) - The U.S. Food and Drug Administration has approved Moderna's respiratory syncytial virus (RSV) vaccine, the company announced on Friday, giving it a shot at much-needed new revenue from a second product.

Read more
30 May 2024 20:56

What to know about bird flu in dairy cows and the risk to humans

CHICAGO, May 30 (Reuters) - A third U.S. dairy worker tested positive for bird flu after exposure to infected cows, and was the first to suffer respiratory symptoms, U.S. officials said on Thursday in the latest expansion of the outbreak. Bird flu has been found in dairy cattle in nine states. This second case in a Michigan dairy worker was found through increased testing of people and cows in the state following the April 1 identification of a case in a Texas farm worker. Here's what you need to know about the outbreak.

WHY IS H5N1 OR BIRD FLU A CONCERN?

Read more
30 May 2024 09:23

LONDON BROKER RATINGS: Jefferies and UBS cut Anglo American

(Alliance News) - The following London-listed shares received analyst recommendations Thursday morning and on Wednesday:

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.